Panaxia Labs Israel Ltd

TA:HROD Israel Other
Market Cap
$111.99K
ILA41.77 Million ILA
Market Cap Rank
#40727 Global
#372 in Israel
Share Price
ILA4336.00
Change (1 day)
+1.76%
52-Week Range
ILA4001.00 - ILA9845.00
All Time High
ILA12670.00
About

Panaxia Pharmaceutical Industries Ltd provides pharmaceutical solutions for patients and physicians. The company offers pharma-grade smokeless cannabis products, such as oral and sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches. Panaxia Pharmaceutical Industries Ltd has strategic partnerships with Ultra Health,… Read more

Panaxia Labs Israel Ltd (HROD) - Net Assets

Latest net assets as of June 2019: ILA-20.53 Million ILA

Based on the latest financial reports, Panaxia Labs Israel Ltd (HROD) has net assets worth ILA-20.53 Million ILA as of June 2019.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA11.33 Million) and total liabilities (ILA31.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA-20.53 Million
% of Total Assets -181.24%
Annual Growth Rate -12.79%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 26.97

Panaxia Labs Israel Ltd - Net Assets Trend (2015–2018)

This chart illustrates how Panaxia Labs Israel Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Panaxia Labs Israel Ltd (2015–2018)

The table below shows the annual net assets of Panaxia Labs Israel Ltd from 2015 to 2018.

Year Net Assets Change
2018-12-31 ILA11.66 Million +28.88%
2017-12-31 ILA9.04 Million -29.99%
2016-12-31 ILA12.92 Million -26.50%
2015-12-31 ILA17.57 Million --

Equity Component Analysis

This analysis shows how different components contribute to Panaxia Labs Israel Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 502600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2018)

Component Amount Percentage
Common Stock ILA13.97 Million 81.89%
Other Components ILA92.92 Million 544.77%
Total Equity ILA17.06 Million 100.00%

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Panaxia Labs Israel Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2017 to 2018, total equity changed from 13,935,000 to 17,057,000, a change of 3,122,000 (22.4%).
  • Net income of 2,732,000 contributed positively to equity growth.
  • Other factors increased equity by 390,000.

Equity Change Factors (2017 to 2018)

Factor Impact Contribution
Net Income ILA2.73 Million +16.02%
Other Changes ILA390.00K +2.29%
Total Change ILA- 22.40%

Book Value vs Market Value Analysis

This analysis compares Panaxia Labs Israel Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently Panaxia Labs Israel Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 16.02%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.06x
  • Recent ROE (16.02%) is above the historical average (-14.68%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -24.60% 0.00% 0.00x 1.54x ILA-7.73 Million
2016 -29.29% 0.00% 0.00x 1.69x ILA-6.88 Million
2017 -20.85% 0.00% 0.00x 1.93x ILA-4.30 Million
2018 16.02% 0.00% 0.00x 1.06x ILA1.03 Million

Industry Comparison

This section compares Panaxia Labs Israel Ltd's net assets metrics with peer companies in the Other industry.

Industry Context

  • Industry: Other
  • Average net assets among peers: $38,238,889
  • Average return on equity (ROE) among peers: -24.81%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Panaxia Labs Israel Ltd (HROD) ILA-20.53 Million -24.60% N/A $112.83K
Biomedix Incubator Ltd (BMDX) $22.00 Million -65.28% 0.03x $127.40K
Black Sea Property PLC Ordinary Shares (BSP) $1.91 Million -202.26% 1.13x $59.37K
Ai Conversation Systems Ltd (FVT) $22.19 Million 66.99% 2.97x $8.00K
Gamatronic Electronic Industries Ltd (GAMT) $108.08 Million 0.13% 0.24x $38.38K
The Israel Land Development Company Ltd (ILDA) $21.85 Million -30.46% 0.50x $30.98K
Insuline Medical Ltd (INSL) $-2.26 Million 0.00% 0.00x $7.11K
Itay Financial A.A Investments Ltd (ITYF) $20.94 Million 32.06% 24.49x $10.58K
Micronet Ltd (MCRNL) $62.64 Million -1.68% 0.65x $13.95K
Netz Hotels Ltd (NZHT) $86.81 Million -22.84% 0.00x $1.52K